Ultra Rapid Detoxification (UROD) — CPB 0317 | AETNA Coverage Update

TL;DR: Aetna maintains its position under CPB 0317 that ultra rapid detoxification (UROD) is experimental, investigational, or unproven — meaning no reimbursement for this procedure, full stop. This modified policy, with an effective date of 2025-12-18, matters to any practice or facility billing HCPCS J2312 or J2313 alongside F11.1x or F11.2x diagnosis codes in the context of UROD services.

If your team has been billing UROD as part of opioid use disorder treatment for Aetna members, this update is a hard stop. The Aetna UROD coverage policy under CPB 0317 leaves no gray area. The procedure is non-covered across all indications — and that hasn't changed with this modification.

Quick-Reference Table

Aetna Ultra Rapid Detoxification Coverage Criteria and Medical Necessity Requirements 2025

The Aetna ultra rapid detoxification coverage policy is categorical: UROD does not meet medical necessity criteria under any clinical scenario Aetna recognizes. No diagnosis code, no patient history, no provider credentials, and no facility type changes that conclusion.

The billing guidelines under CPB 0317 apply across all plan types Aetna administers where this bulletin governs. If you bill HCPCS J2312 (naloxone hydrochloride injection, 0.01 mg, not otherwise specified) or J2313 (naloxone hydrochloride [Zimhi] injection, 0.01 mg) in the context of a UROD procedure, those claims are at risk.

The real issue here is documentation. If a claim pulls in J2312 or J2313 with opioid use disorder diagnosis codes in an inpatient or monitored anesthesia setting, your medical records need to be clean about what service was actually rendered. UROD billing in that context is a fast path to a claim denial and a potential audit flag.

Aetna UROD Exclusions and Non-Covered Indications

Aetna's position on UROD is absolute. The policy text covers two bases: UROD as a clinical detoxification treatment, and UROD for all other indications. There is no carve-out. There is no exception pathway.

This matters because some practices have attempted to bill components of a UROD procedure separately — the anesthesia, the naloxone administration, the monitoring. Aetna's coverage policy makes the entire UROD encounter non-covered, not just the label. Unbundling a UROD procedure to recover partial reimbursement is a billing pattern that can trigger post-payment audits. Don't do it.

The 23 ICD-10 codes in this policy span opioid abuse (F11.10–F11.19), opioid dependence (F11.20–F11.29), poisoning by opiates and related narcotics (T40-series), and adverse effects of opioids and methadone. That's the full clinical picture of opioid use disorder billing. Every patient scenario where UROD might come up is mapped here, and Aetna's answer is the same for all of them: not covered.

If you're treating a provider or facility that offers UROD as part of a broader addiction medicine program, talk to your compliance officer before December 18, 2025. The financial exposure on these claims isn't limited to the UROD service itself — it can extend to associated charges in the same episode of care.

Coverage Indications at a Glance

Aetna UROD Billing Guidelines and Action Items 2025

Here's what your billing team and revenue cycle staff need to do now.

HCPCS and ICD-10 Codes Under CPB 0317

HCPCS Codes — Non-Covered in UROD Context

These two HCPCS codes are associated with naloxone hydrochloride administration. In the context of UROD, Aetna treats claims involving these codes as non-covered under CPB 0317.

ICD-10-CM Diagnosis Codes

These are the diagnosis codes Aetna maps to this policy. All 23 codes represent the clinical spectrum of opioid use disorder, opioid poisoning, and opioid adverse effects. Every row is a scenario where UROD billing might surface — and every one carries the same non-covered determination under CPB 0317.

The F11.1x and F11.2x entries below are subcategory codes. The source policy lists them individually but describes them only as "Opioid abuse" and "Opioid dependence" respectively. That's how they appear here.

One practical note on the T40 codes: these cover poisoning and adverse effect scenarios. CPB 0317 maps them to the UROD non-coverage determination. If you're billing naloxone in a different clinical context entirely, make sure your documentation clearly supports that the service is outside the scope of a UROD encounter. The distinction matters for claim review.